| 3.45 -0.2 (-5.48%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.56 | 1-year : | 14.97 |
| Resists | First : | 9.04 | Second : | 12.81 |
| Pivot price | 3.96  |
|||
| Supports | First : | 2.94 | Second : | 2.44 |
| MAs | MA(5) : | 3.67 |
MA(20) : | 4.99 |
| MA(100) : | 11.56 |
MA(250) : | 11.21 |
|
| MACD | MACD : | -1.8 |
Signal : | -2 |
| %K %D | K(14,3) : | 15.5 |
D(3) : | 15 |
| RSI | RSI(14): 21.9 |
|||
| 52-week | High : | 19.1 | Low : | 2.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CATX ] has closed above bottom band by 31.4%. Bollinger Bands are 29.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.74 - 3.76 | 3.76 - 3.78 |
| Low: | 3.37 - 3.4 | 3.4 - 3.42 |
| Close: | 3.41 - 3.45 | 3.45 - 3.48 |
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Wed, 11 Dec 2024
Walleye Capital LLC Sells 494,706 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Sat, 07 Dec 2024
Perspective Therapeutics, Inc. (NYSE:CATX) Director Acquires $100,003.75 in Stock - MarketBeat
Wed, 04 Dec 2024
Perspective Therapeutics CEO Johan Spoor buys $30,132 in stock - Investing.com
Wed, 27 Nov 2024
Perspective Therapeutics to Present at Piper and Evercore Healthcare Conferences in December | CATX Stock News - StockTitan
Sat, 23 Nov 2024
Perspective Therapeutics stock downgraded to Neutral - Investing.com
Thu, 21 Nov 2024
Perspective stock slips after radio pharma data (CATX:NYSE) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 4.336e+007 (%) |
| Held by Institutions | 20.4 (%) |
| Shares Short | 6,780 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.727e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 711.5 % |
| Return on Equity (ttm) | -12.1 % |
| Qtrly Rev. Growth | 1.46e+006 % |
| Gross Profit (p.s.) | -7.25 |
| Sales Per Share | -16 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.2 |
| Price to Book value | 0 |
| Price to Sales | -0.22 |
| Price to Cash Flow | 0.98 |
| Dividend | 0 |
| Forward Dividend | 6.42e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|